Tumor antigen peptide

A method of treating a lung cancer or a female reproductive organ cancer comprising intravenously or subcutaneously administering to a subject with the lung cancer or the female reproductive organ cancer:

• (a) a polypeptide comprising the amino acids of SEQ ID NO:
• 3, SEQ ID NO:
• 10, SEQ ID NO:
• 65, SEQ ID NO:
• 66, SEQ ID NO:
• 67 or SEQ ID NO:
• 72 and having HLA-A11 antigen-binding capacity or HLA-A24 antigen-binding capacity, or
• (b) a polypeptide comprising the amino acids of SEQ ID NO:
• 4, SEQ ID NO:
• 5, SEQ ID NO:
• 10, SEQ ID NO:
• 47, or SEQ ID NO:
• 57, and having HLA-A2 antigen binding capacity,
• wherein the administered polypeptide induces CTL upon contact with PBLs in the subject expressing on the cell surface the HLA-A11 antigen or the HLA-A24 antigen or the polypeptide of (b) with the PBLs expressing on the cell surface the HLA-A2 antigen,
• wherein the lung cancer or the cancer in a female specific reproductive organ cancer expresses a BORIS gene belonging to isoform A or C or a BORIS gene belonging to subfamily 5 or 6,
• wherein the subject administered the polypeptide of (a) is the HLA-A11 antigen positive or the HLA-A24 antigen positive, or the subject administered the polypeptide of (b) is the HLA-A2 antigen positive, and
• wherein the CTL induction treats the lung cancer or the female reproductive organ cancer.